
# Manifestation of overt diabetes on growth hormone treatment


## Dr. M. Madhusudhana, , Dr. V. Mathew, J. Marrow, L. Willingham, Dr. S. Gupta

### HULL ROYAL INFIRMARY

- ❖ A 14 year old girl with background of cerebral palsy (functionally grade 4), global developmental delay, panhypopituitarism(diagnosed at 12 yrs of age).
- Medications: growth hormone(GH)(1.4 mg/day), thyroxine and hydrocortisone
- Height measurement was always an issue due to significant scoliosis and contractures.




- Presented with chest infection, found to be persistently hyperglycemic(HbA1c 9%), autoantibody screen was negative
- Treated with insulin.( needed a large dose-2U/kg/day)
- Around the same time, dose of GH reduced to adult dose(0.2 mg/day) as her Insulin like growth factor-1(IGF-1) levels were high and she had completed her growth.
- Her insulin requirement drastically reduced over a period of a month.
- ❖ She continued to take a small dose of levamir (5 units), but had to wean it off due to hypoglycemic episodes, stopped after a year.
- Her blood sugars and HbA1c remain normal, now off insulin for nearly 2 years



- It is of note that her IGF-1 levels were high for a period of at least 6 months before she was diagnosed with diabetes.
- Improvement in her diabetes coincided with reduction of GH dose. And gradual normalisation of HBA1c correlated with normal IGF-1 levels.

#### RELATIONSHIP BETWEEN GH AND IGF-1 LEVELS



#### CONCLUSION

A significantly disabled teenager developed iatrogenic diabetes on GH treatment, needed insulin, which, however reversed on reducing the GH to adult maintenance dose.

#### LEARNING POINTS

- ❖ GH replacement therapy can increase insulin resistance(1). Hence the need to monitor HbA1C levels during GH therapy.
- Fasting insulin levels are needed to document insulin resistance in any case of atypical diabetes.
- Height can be very difficult to measure in a child with significant disability, hence completion of growth difficult to assess.
- Completion of growth is an indication to stop/reduce GH therapy depending on etiology(3).
- If supraphysiological levels of GH are maintained (as in acromegaly) insulin resistance increases and can precipitate diabetes.
- ❖ It is recommended that GH doses be gradually reduced after epiphyseal closure, using serum IGF-I concentration as a guide with the aim of maintaining serum IGF-I levels within the ageappropriate normal range(2).

#### REFERENCES

- Andrea F. Attanasio et al Prevalence and Incidence of Diabetes Mellitus in Adult Patients on Growth Hormone Replacement for Growth Hormone Deficiency: A Surveillance Database Analysis. J Clin Endocrinol Metab, July 2011, 96(7):2255–2261
- 2. Wilson et al Update of Guidelines for the Use of Growth Hormone in Children: The Lawson Wilkins Pediatric Endocrinology Society Drug and Therapeutics Committee . The Journal of Pediatrics October 2003 :415-421
- 3. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML (2009) American Association of clinical endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients.update. Endocr Pract 15(Suppl 2):1–29